EUVIMEDEUVIMED entdecken
Crossref

Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status

Tatsiana Pukhalskaya, Mitchell Finkelstein, Dacia A Miyake-Caballero, Michael T Tetzlaff, Jeffrey P North iD, Jarish N Cohen iD

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.14775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2025. Verfasst von Tatsiana Pukhalskaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Pathology, University of California, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Exfoliative, Interleukin-13, Cytokines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T‐cell lymphoma. Most of these are typified by Type 2 (e.g., eczema) or Type 17 (e.g., psoriasis) immune activation. However, since the clinicopathologic features of erythroderma can be nonspecific, assays that determine the underlying immune activation status are desirable.

Methods

IL‐13 RNA in situ hybridization and IL‐36 immunohistochemistry were performed on 30 specimens of erythroderma, to ascertain Type 2 and Type 17 immune signatures, respectively.

Results

Specimens of erythrodermic psoriasis and PRP showed strong expression of IL‐36 and less than one IL‐13‐positive cell per millimeter. Conversely, those of spongiotic dermatitis showed low expression of IL‐36 and greater than one IL‐13‐positive cell per millimeter. Most specimens of spongiotic, psoriasiform dermatitis demonstrated low IL‐36 expression and greater than one IL‐13‐positive cell per millimeter, but a subset showed high IL‐36 expression and greater than one IL‐13‐positive cell per millimeter.

Conclusions

We developed a Type 2/17 immune signature classifier based on cytokine profiling, which showed that cases of erythroderma fall within distinct categories of immune activation. This categorization may have utility in guiding clinical decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, ExfoliativeInterleukin-13CytokinesHumansBiopsyMalePsoriasisFemaleInterleukin-1ImmunohistochemistryMiddle AgedAdultAged

Stichwörter der Autor:innen

IL‐13IL‐36erythrodermapsoriasisspongiotic dermatitis

Substanzen

Interleukin-1Interleukin-13interleukin 36, humanCytokines

Autor:innen und Institutionen

  • Department of Dermatology and Pathology, University of California, California, USA.
  • Cooper Medical School of Rowan University, Camden, New Jersey, USA.

ORCID-Profile: Jeffrey P North, Jarish N Cohen

Zitieren

APA

Pukhalskaya, T., Finkelstein, M., Miyake-Caballero, D. A., Tetzlaff, M. T., North, J. P., & Cohen, J. N. (2025). Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14775

Vancouver

Pukhalskaya T, Finkelstein M, Miyake-Caballero DA, Tetzlaff MT, North JP, Cohen JN. Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14775

BibTeX
@article{Pukhalskaya2025,
  author = {Pukhalskaya, Tatsiana and Finkelstein, Mitchell and Miyake-Caballero, Dacia A and Tetzlaff, Michael T and North, Jeffrey P and Cohen, Jarish N},
  title = {Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.14775}
}
Kostenlos starten →